__NUXT_JSONP__("/drugs/Enzalutamide", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:c,conditionIndication:"Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.",inn:c,marketingAuthorisationDate:"2013-06-21 00:00:00",marketingAuthorisationHolder:"Astellas Pharma Europe B.V.",medicineName:b,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fxtandi"}],fdaDrugLabel:[{brand:b,indication:"1 INDICATIONS AND USAGE XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with: • castration-resistant prostate cancer. ( 1 ) • metastatic castration-sensitive prostate cancer. ( 1 )",manufacturer:"Astellas Pharma US, Inc.",splSetId:"b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf"}],id:a,nciThesaurus:{casRegistry:"915087-33-1",chebiId:"",chemicalFormula:"C21H16F4N4O2S",definition:"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.",fdaUniiCode:"93T0T9GKNU",identifier:"C71744",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C146993"],synonyms:["ASP9785","Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-","ENZALUTAMIDE",a,"MDV3100",b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FEnzalutamide",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Enzalutamide","Xtandi","enzalutamide","2021-10-30T13:43:52.523Z")));